Edition:
United Kingdom

Aridis Pharmaceuticals Inc (ARDS.OQ)

ARDS.OQ on NASDAQ Stock Exchange Capital Market

7.95USD
10 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.95
Open
$8.80
Day's High
$8.80
Day's Low
$7.65
Volume
1,744
Avg. Vol
--
52-wk High
$13.85
52-wk Low
$7.59

Latest Key Developments (Source: Significant Developments)

Aridis Expands Research Agreement With Cystic Fibrosis Foundation & Is Awarded FDA Expedited Program Designations
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Aridis Pharmaceuticals Inc ::ARIDIS EXPANDS RESEARCH AGREEMENT WITH THE CYSTIC FIBROSIS FOUNDATION AND IS AWARDED FDA EXPEDITED PROGRAM DESIGNATIONS.ARIDIS PHARMACEUTICALS INC - FDA CLEARS AR-501 TO INITIATE HUMAN CLINICAL TESTING.ARIDIS PHARMACEUTICALS INC - FDA GRANTS FAST-TRACK AND QIDP DESIGNATIONS FOR AR-501, ENABLING FUTURE PRIORITY REVIEW STATUS.ARIDIS PHARMACEUTICALS INC - CF FOUNDATION EXPANDS RESEARCH AGREEMENT FOR AR-501 TO INCLUDE ADDITIONAL AWARD AMOUNT OF UP TO $4.6 MILLION.ARIDIS PHARMACEUTICALS - CF FOUNDATION MORE THAN DOUBLED RESEARCH AGREEMENT FOR CLINICAL DEVELOPMENT OF AR-501 FROM $2.9 MILLION TO UP TO $7.5 MILLION.ARIDIS PHARMACEUTICALS INC - INTENDS TO INITIATE PHASE 1/2A CLINICAL TRIAL NEXT MONTH FOR AR-501.ARIDIS PHARMACEUTICALS INC - INTENDS TO INITIATE PHASE 1/2A CLINICAL TRIAL NEXT MONTH FOR AR-501.  Full Article

Aridis Pharmaceuticals Q3 Loss Per Share $1.97
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aridis Pharmaceuticals Inc ::ARIDIS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND CORPORATE OVERVIEW.Q3 REVENUE $1.0 MILLION.Q3 REVENUE VIEW $519,000 -- THOMSON REUTERS I/B/E/S.Q3 LOSS PER SHARE $1.97.Q3 EARNINGS PER SHARE VIEW $-1.05 -- THOMSON REUTERS I/B/E/S.ON TRACK FOR AR-105 GLOBAL PHASE 2 CLINICAL STUDY COMPLETION MID-2019.ARIDIS PHARMACEUTICALS - AS OF SEPT 30, CO HAD CASH AND CASH EQUIVALENTS OF $34.1 MILLION, WHICH CO BELIEVES IS SUFFICIENT TO FUND OPERATIONS INTO 2020.  Full Article

Aridis Pharmaceuticals And Hepalink Entered Amendment To JV Agreement
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd <002399.SZ>::ARIDIS PHARMACEUTICALS - ON AUG 24, CO AND HEPALINK ENTERED AMENDMENT TO JV AGREEMENT .ARIDIS PHARMACEUTICALS-PURSUANT TO AMENDMENT, CO TO GRANT AR-105 PRODUCT CANDIDATE LICENSE TO SABC, HEPALINK TO CONTRIBUTE ADDITIONAL $1.2 MILLION TO SABC.ARIDIS PHARMACEUTICALS - PURSUANT TO JV AGREEMENT AND AMENDMENT, HEPALINK IS OBLIGATED TO CONTRIBUTE EQUIVALENT OF $7.2 MILLION TO SABC.  Full Article

Aridis' shares rise in muted market debut

Biotechnology company Aridis Pharmaceuticals Inc rose as much as 5.4 percent to $13.70 in its U.S. market debut on Tuesday, joining a host of other small-cap biotechs that have gone public this year.